Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RBD SARS-CoV-2 HBsAg VLP vaccine - Serum Institute of India/SpyBiotech

Next Previous
X
Search
Drug Profile

RBD SARS-CoV-2 HBsAg VLP vaccine - Serum Institute of India/SpyBiotech

Alternative Names: Receptor Binding Domain (RBD) COVID-19 Vaccine - Serum Institute of India/SpyBiotech; Receptor binding domain SARS-CoV-2 hepatitis B surface antigen virus like particle vaccine - Serum Institute of India/SpyBiotech; Virus-like particle (VLP) vaccine - Serum Institute of India/SpyBiotech

Latest Information Update: 09 Dec 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SpyBiotech
  • Developer Serum Institute of India; SpyBiotech
  • Class COVID-19 vaccines; Subunit vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II COVID 2019 infections

Most Recent Events

  • 01 Dec 2020 Serum Institute of India plans a phase I/II trial in COVID-2019 infections (In volunteers, In adults, In the elderly) in Australia (IM) in December 2020
  • 08 Sep 2020 SpyBiotech and Serum Institute of India agree to co-develop RBD SARS-CoV-2 HBsAg VLP vaccine for COVID-2019 infections
  • 22 Aug 2020 Phase-I/II clinical trials in COVID-2019 infections (In volunteers, In adults, In the elderly) in Australia before September 2020 (IM) (ACTRN12620000817943)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top